Evaluation of Olaparib Efficacy Following CDK4/6 Inhibitor Therapy in BRCA-Mutated, Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: A Turkish Oncology Group (TOG) Study

Zeynep Sıla Gökdere, Taha Koray Şahin, İrem Bilgetekin, Naziyet Köse Baytemur, Mustafa Seyyar, Melike Yazıcı, Ercan Gümüşburun, Seval Akay, Damla Günenç, Çağla Karaoğlu, Pınar Ezgi Dama, Ece Şahin Hafızoğlu, Serkan Menekşe, Berkan Karadurmuş, Talha Özüdoğru, Galip Can Uyar, Görkem Turhan, Bahadır Köylü, Ferit Turan, Ayşe Nuransoy Cengiz, Ali Kaan Güren, Osman Bütün, Cevher Burcu Salman, Aslı Geçgel, Şüheda Ataş İpek, Esra Asarkaya, Bedriye Açıkgöz Yıldız, Ahmet Ünlü, Elif Şahin, Ekin Akyıldız Usta, Hüseyin Kanmaz, Ece Esin, Engin Erdemoğlu, Atilla Yıldırım, Musa Barış Aykan, Tülay Kuş, Mustafa Şahbazlar, Erdem Çubukçu, Hüseyin Salih Semiz, Fatih Selçukbiricik, Mevlüde İnanç, Murat Sarı, Bülent Karabulut, Hatice Odabaş, Ertuğrul Bayram, Gamze Gököz Doğu, Banu Öztürk, Zeynep Gülsüm Güç, Ulus Ali Şanlı, Burcu Çakar, Erhan Gökmen, Berna Çakmak Öksüzoğlu, Devrim Çabuk, Sercan Aksoy, Hasan Çağrı Yıldırım

Open source

DOI: 10.1007/s11523-026-01261-w
Published: 2026-10-22
Container: Targeted Oncology
Publisher: Springer Science and Business Media LLC
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1007/s11523-026-01261-w,
  title = {Evaluation of Olaparib Efficacy Following CDK4/6 Inhibitor Therapy in BRCA-Mutated, Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: A Turkish Oncology Group (TOG) Study},
  author = {Zeynep Sıla Gökdere and Taha Koray Şahin and İrem Bilgetekin and Naziyet Köse Baytemur and Mustafa Seyyar and Melike Yazıcı and Ercan Gümüşburun and Seval Akay and Damla Günenç and Çağla Karaoğlu and Pınar Ezgi Dama and Ece Şahin Hafızoğlu and Serkan Menekşe and Berkan Karadurmuş and Talha Özüdoğru and Galip Can Uyar and Görkem Turhan and Bahadır Köylü and Ferit Turan and Ayşe Nuransoy Cengiz and Ali Kaan Güren and Osman Bütün and Cevher Burcu Salman and Aslı Geçgel and Şüheda Ataş İpek and Esra Asarkaya and Bedriye Açıkgöz Yıldız and Ahmet Ünlü and Elif Şahin and Ekin Akyıldız Usta and Hüseyin Kanmaz and Ece Esin and Engin Erdemoğlu and Atilla Yıldırım and Musa Barış Aykan and Tülay Kuş and Mustafa Şahbazlar and Erdem Çubukçu and Hüseyin Salih Semiz and Fatih Selçukbiricik and Mevlüde İnanç and Murat Sarı and Bülent Karabulut and Hatice Odabaş and Ertuğrul Bayram and Gamze Gököz Doğu and Banu Öztürk and Zeynep Gülsüm Güç and Ulus Ali Şanlı and Burcu Çakar and Erhan Gökmen and Berna Çakmak Öksüzoğlu and Devrim Çabuk and Sercan Aksoy and Hasan Çağrı Yıldırım},
  year = {2026},
  journal = {Targeted Oncology},
  doi = {10.1007/s11523-026-01261-w},
  url = {https://doi.org/10.1007/s11523-026-01261-w}
}

RIS

TY  - JOUR
TI  - Evaluation of Olaparib Efficacy Following CDK4/6 Inhibitor Therapy in BRCA-Mutated, Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: A Turkish Oncology Group (TOG) Study
AU  - Zeynep Sıla Gökdere
AU  - Taha Koray Şahin
AU  - İrem Bilgetekin
AU  - Naziyet Köse Baytemur
AU  - Mustafa Seyyar
AU  - Melike Yazıcı
AU  - Ercan Gümüşburun
AU  - Seval Akay
AU  - Damla Günenç
AU  - Çağla Karaoğlu
AU  - Pınar Ezgi Dama
AU  - Ece Şahin Hafızoğlu
AU  - Serkan Menekşe
AU  - Berkan Karadurmuş
AU  - Talha Özüdoğru
AU  - Galip Can Uyar
AU  - Görkem Turhan
AU  - Bahadır Köylü
AU  - Ferit Turan
AU  - Ayşe Nuransoy Cengiz
AU  - Ali Kaan Güren
AU  - Osman Bütün
AU  - Cevher Burcu Salman
AU  - Aslı Geçgel
AU  - Şüheda Ataş İpek
AU  - Esra Asarkaya
AU  - Bedriye Açıkgöz Yıldız
AU  - Ahmet Ünlü
AU  - Elif Şahin
AU  - Ekin Akyıldız Usta
AU  - Hüseyin Kanmaz
AU  - Ece Esin
AU  - Engin Erdemoğlu
AU  - Atilla Yıldırım
AU  - Musa Barış Aykan
AU  - Tülay Kuş
AU  - Mustafa Şahbazlar
AU  - Erdem Çubukçu
AU  - Hüseyin Salih Semiz
AU  - Fatih Selçukbiricik
AU  - Mevlüde İnanç
AU  - Murat Sarı
AU  - Bülent Karabulut
AU  - Hatice Odabaş
AU  - Ertuğrul Bayram
AU  - Gamze Gököz Doğu
AU  - Banu Öztürk
AU  - Zeynep Gülsüm Güç
AU  - Ulus Ali Şanlı
AU  - Burcu Çakar
AU  - Erhan Gökmen
AU  - Berna Çakmak Öksüzoğlu
AU  - Devrim Çabuk
AU  - Sercan Aksoy
AU  - Hasan Çağrı Yıldırım
PY  - 2026
JO  - Targeted Oncology
DO  - 10.1007/s11523-026-01261-w
UR  - https://doi.org/10.1007/s11523-026-01261-w
ER  -

APA

Gökdere, Z. S., Şahin, T. K., Bilgetekin, İ., Baytemur, N. K., Seyyar, M., Yazıcı, M., Gümüşburun, E., Akay, S., Günenç, D., Karaoğlu, Ç., Dama, P. E., Hafızoğlu, E. Ş., Menekşe, S., Karadurmuş, B., Özüdoğru, T., Uyar, G. C., Turhan, G., Köylü, B., Turan, F., Cengiz, A. N., Güren, A. K., Bütün, O., Salman, C. B., Geçgel, A., İpek, Ş. A., Asarkaya, E., Yıldız, B. A., Ünlü, A., Şahin, E., Usta, E. A., Kanmaz, H., Esin, E., Erdemoğlu, E., Yıldırım, A., Aykan, M. B., Kuş, T., Şahbazlar, M., Çubukçu, E., Semiz, H. S., Selçukbiricik, F., İnanç, M., Sarı, M., Karabulut, B., Odabaş, H., Bayram, E., Doğu, G. G., Öztürk, B., Güç, Z. G., Şanlı, U. A., Çakar, B., Gökmen, E., Öksüzoğlu, B. Ç., Çabuk, D., Aksoy, S., & Yıldırım, H. Ç. (2026). Evaluation of Olaparib Efficacy Following CDK4/6 Inhibitor Therapy in BRCA-Mutated, Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: A Turkish Oncology Group (TOG) Study. Targeted Oncology. https://doi.org/10.1007/s11523-026-01261-w

Source records

crossref · retrieved 2026-11-09T10:45:31.002Z